Adult Cystic Fibrosis

Evidence-based Respiratory Medicine

Volumn , Issue , 2007, Pages 361-388

  Kolbe, John ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Adult cystic fibrosis; Airway clearance techniques; CF mutations; DNase; Exercise tolerance

Indexed keywords

EID: 80052676439     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987377.ch29     Document Type: Chapter

References (211)

1. Riordan JA,Rommens JM,Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science 1989; 245:1066-73.
2. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000; 67:117-33.
3. Hamosh A,Corey M. Correlation between genotype and phenotype in patients with cystic fibrosis. The Cystic Fibrosis Genotype-Phenotype Consortium. N Engl J Med 1993; 329:1308-13 (see also ref. 5).
4. Gan KH, Veeze HJ, van den Ouwland MW et al. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 1995; 333:95-9.
5. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993; 329:1308-13 (see also ref. 3).
6. Gan K,Guess WP,Bakker W et al. Genetic and clinical features of patients diagnosed with cystic fibrosis after the age of 16 years. Thorax 1995; 50:1301-4.
7. Schechter MS,Shelton BJ,Margolis PA,Fitzsimmons SC. The association of socio-economic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001; 163:1331-7.
8. Mahadeva R,Sharples L,Ross-Russell RI,Webb AK,Bilton D,Lomas DA. Association of a-1-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis. Thorax 2001: 56:53-8.
9. Grasemann H, Storm van's Gravesande K,Buscher R et al. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167:390-4.
10. Arkwright PD, Pravica V, Geraghty PJ et al. End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. AmJ Respir Crit Care Med 2003; 167:384-9.
11. Friedman KJ,Heim RA,Knowles MR, Silverman LM. Rapid characterisation of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: association of the 5T allele with selected CFTR mutations and its incidence in atypical non-pulmonary disease. Hum Mutat 1997; 10:108-15.
12. Gervois R,Lafitte J-J,Dunmur V et al. Sweat chloride and ??F508 mutation in chronic bronchitis or bronchiectasis. Lancet 1993; 342:997.
13. Giroden E, Cazeneune C, Lebargy F et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 1997; 5:149-55.
14. Shorer N,Schwarz M,Malone G et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998; 339:645-52.
15. Anderson DH. Cystic fibrosis of the pancreas and its relation to celiac disease. A clinical and pathologic study. Am J Child 1938; 56:344-99.
16. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991; 46:881-5.
17. Epidemiologic Registry of Cystic Fibrosis Advisory Board. CRCF Annual Report 1998. North Ryde,NSW.
18. Fitzsimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1-9.
19. Kerem E, Reisman J, Carey M et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187-91.
20. Sharma R, Florea VC, Bolger AP et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001; 56:746-50.
21. Blair E, Cull A, Freeman CP. Psychosocial functioning of young adults with cystic fibrosis and their families. Thorax 1994; 49:798-802.
22. Matsui H, Grubb BR, Tarron R et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airway disease. Cell 1998; 95:1005-15.
23. Smith JJ, Travis SM,Greenberg EP,Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229-36.
24. Konstan MW,Hilliard KA,Norwell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggests ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150:448-54.
25. Armstrong DS, Grimwood K, Carlin JB et al. Lower airway inflammation in infants and young children with cystic fibrosis. AmJ Respir Crit Care Med 1997; 156:1197-204.
26. Dakin Cj,Numa AH,Wang H,Morton JR,Vertzyas CC,Henry RL. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. AmJ Respir Crit Care Med 2002; 165:904-10.
27. Muhlebach MS, Noah TL. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med 2002; 165:911-15.
28. Van der Vliet A, Nguyen MN, Shigenoga MK, Eiserich JP,Marelich GP, Cross CE. Myeloperoxidase and protein oxidation in cystic fibrosis. AmJ Physiol Lung Cell Mol Physiol 2000; 279:L537-46.
29. Torrens JK, Dawkins P, Conway SP, Moya E. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998; 53:182-5.
30. Spector ML, Stern RC. Pneumothorax in cystic fibrosis: a 26 year experience. Ann Thorac Surg 1989; 47:204-7.
31. Antonelli M,Midulla F,Tancredi G et al. Bronchial artery embolization for the management of nonmassive hemoptysis in cystic fibrosis. Chest 2002; 121:796-801.
32. Barben J, Robertson D, Olinsky A, Ditchfield M. Bronchial artery embolization for hemoptysis in young patients with cystic fibrosis. Radiology 2002; 224:124-30.
33. Becker JW,Burke W,McDonald G et al. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 1996; 109:1536-40.
34. Greenberger PA. Allergic bronchopulmonary aspergillus. J Allergy Clin Immunol 2002; 110:685-92.
35. Duff AJA. Psychological consequences of segregation resulting from chronic Burkholderia cepacia complex infection in adults with CF. Thorax 2002; 57:758.
36. Ledson MJ, Gallagher MJ, Jackson M, Hart CA,Walshaw MJ. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002; 57:142-5.
37. Pitt TL, Kaufmann ME, Patel PS et al. Type characteristics and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the UK and the Republic of Ireland. J Microbiol 1996; 44:203-10.
38. Wallace RJ Jr, Glassroth J,Griffith DE, Olivier KN,Cook JL, Gordon F. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. AmJ Respir Crit Care Med 1997; 156:S1-S25.
39. Al Samarrai T,Zhong N,Lamont I et al. A fast, highly discriminating and inexpensive method for computer-assisted typing of Pseudomonas aeruginosa. J Clin Microbiol 2000; 38:4445-52.
40. Speert DP, Campbell ME, Henry DA et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. AmJ Respir Crit Care Med 2002; 166:988-93.
41. Pedersen SS, Jensen T, Pressler T, Hoiby N, Rosendal K. Does centralised treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection? Acta Pediatr Scand 1986; 75:840-5.
42. Tubbs D, Lenney W, Alcock P, Campbell CA, Gray J, Pantin C. Pseudomonas aeruginosa in cystic fibrosis: cross-infection and the need for segregation. Respir Med 2001; 95:147-52.
43. Jones AM,Dodd ME, Doherty CJ,Govan JRW,Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002; 57:924-5.
44. Cheng K, Smyth RL, Govan JR et al. Spread of b-lactam resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996; 348:639-42.
45. Jones AM, Govan JR, Doherty CJ et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001; 358:557-8.
46. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000; 29:177-81.
47. McCallum SJ,Corkill J, Gallagher M,Ledson MJ,Hart CA,Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by Pseudomonas aeruginosa. Lancet 2001; 358:558-60.
48. Anthony M, Rose B, Beard Pegler M et al. Genetic analysis of Pseudomonas aeruginosa isolates from the sputa of Australian adult cystic fibrosis patients. J Clin Microbiol 2002; 40:2772-8.
49. Armstrong D, Bell S,Robinson M et al. Evidence for spread of a clon-al strain of Pseudomonas aeruginosa among cystic fibrosis clinics. J Clin Microbiol 2003; 41:2266-7.
50. Fredericksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999; 28:159-66.
51. Farrell PM, Shen G, Splaingard M et al. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 1997; 100:E2.
52. Lebecque P,Leal T, de Boeck C, Jaspers M,Cuppens H, Cassiman J-J. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am J Respir Crit Care Med 2002; 165: 757-61.
53. Veeze HJ,Gan HK,Heijerman HG. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 1995; 333:1644.
54. Rosenstein BJ,Cutting GR for the Cystic Fibrosis Foundation Consensus Panel. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr 1998; 132:589-95.
55. McWilliams T, Wilsher ML, Kolbe J. Cystic fibrosis diagnosed in adulthood. The Green Lane Hospital experience. NZ Med J 2000; 113:6-8.
56. Bush A,Wallis C. Time to think again: cystic fibrosis is not an 'all or none' disease. Pediatr Pulmonol 2000; 30:139-44.
57. British Paediatric Association Working Party on Cystic Fibrosis. Cystic fibrosis in the United Kingdom 1977-85: an improving picture. BMJ 1988: 297:1599-602.
58. Royal College of Physicians. Cystic Fibrosis in Adults: Recommendations for Care of Patients in the United Kingdom. London,Royal College of Physicians of London, 1990.
59. Hill DJ,Martin AJ, Davidson GP et al. Survival of cystic fibrosis patients in South Australia. Evidence that cystic fibrosis center care leads to better survival. Med J Aust 1985; 143:230-2.
60. Mahadeva R,Webb K,Westerbeek RCet al. Clinical outcome in relation to care in centers specialising in cystic fibrosis: cross sectional study. BMJ 1998; 316:1771-5.
61. Walters S,Britton J,Hodson ME. Hospital care for adults with cystic fibrosis: an overview and comparison between special cystic fibrosis clinics and general clinics using a patient questionnaire. Thorax 1994; 49:300-6.
62. Phelan PD, Bowes G. Management of cystic fibrosis in Melbourne, Australia. Thorax 1991; 46:383-4.
63. Cheng K, Smyth RL, Motley J, O'Hea U, Ashby D. Randomised controlled trials in cystic fibrosis (1966-1997) categorised by time, design and intervention. Pediatr Pulmonol 2000: 29:1-7.
64. Gee L,Abbott J,Conway SP,Etherington C,Webb AK. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000; 55:946-54.
65. Kettler LJ, Sawyer SM,Winefield HR,Greville HW. Determinants of adherence in adults with cystic fibrosis. Thorax 2002; 57:459-64.
66. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med 1992; 34:507-13.
67. Abbott J, Dodd M, Bilton D, Webb AK. Treatment compliance in adults with cystic fibrosis. Thorax 1994; 49:115-20.
68. Conway SP,Pond MN,Hamnett T et al. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996; 51:29-33.
69. Conway SP, Pond MN,Watson A et al. Knowledge of adult patients with cystic fibrosis about their illness. Thorax 1996; 51:34-8.
70. Kolbe J. The influence of socioeconomic and psychological factors on patient adherence to self-management strategies. Lessons learned in asthma. Dis Manage Health Outcomes 2002: 10:551-70.
71. Henley LD,Hill ID. Errors, gaps, and misconceptions in the diseaserelated knowledge of cystic fibrosis patients and their families. Pediatrics 1990; 85:1008-13.
72. Levers CE, Brown RT, Drotar D et al. Knowledge of physician prescriptions and adherence to treatment among children with cystic fibrosis and their mothers. J Dev Behav Pediatr 1999; 20:335-43.
73. ATS Statement: guidelines for the six minute walk test. Am J Respir Crit Care Med 2002; 166:111-17.
74. Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999; 54:213-22.
75. Lewis CA, Eaton TE, Fergusson W et al. Home overnight pulse oximetry in COPD patients: more than one recording may be needed. Chest 2003; 123:1127-33.
76. Reiff DB,Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: value in distinguishing between idiopathic and specific types. AJR 1995; 165:261-7.
77. De Jong PA, Nakano Y, Lequin MH, Woods R, Pare PD, Tiddens HAWM. Progression of mucus and bronchiectasis on highresolution CT despite stable lung function tests in children with cystic fibrosis. AmJ Respir Crit Care Med 2003; 167:A323.
78. Sokol RJ,Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Consensus Group. J Pediatr Gastroenterol Nutr 1999; 28:S1-S13.
79. Haworth CS, Selby PC, Horrocks AW,Mawer EB, Adams JE,Webb AK. A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax 2002; 57:719-23.
80. Brenckmann C, Papaioannou A. Biphosphonates for osteoporosis in people with cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
81. Chadwick S,Browning JE,Stern M et al. Nasal application of glycerol in ??F508 cystic fibrosis patients. Thorax 1998; 53:A60.
82. Rubenstein RC, Zeithlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in ??F508 homozygous cystic fibrosis patients. AmJ Respir Crit Care Med 1998; 157:484-90.
83. Knowles MR,Clarke LL,Boucher RL. Activation by intracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991; 325:533-8.
84. Bennett WD,Olivier KN,Zeman KL,Hohnekner KW,Boucher RC, Knowles MR. Effect of uridine 5¢-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996: 153:1796-801.
85. Knowles MR, Church NL, Waltner WE et al. A pilot study of aerosolised amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322:1189-94.
86. Graham A,Hasani A,Alton EWFW et al. No added benefit from nebulised amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6:1243-8.
87. Pons G, Marchand MC, d'Athis P et al. French multicenter randomised double-blind placebo-controlled trial on nebulised amiloride in cystic fibrosis patients. Pediatr Pulmonol 2000; 30:25-31.
88. Peckham DG, Conn A, Chotai C, Lewis S, Knox AJ. Effect of oral digoxin, topical oubain and salbutamol on trans-epithelial nasal potential difference in patients with cystic fibrosis. Clin Sci 1995; 89:277-84.
89. Crystal RG. The gene as a drug. Nature Med 1995: 1:15-17.
90. Wagner JA, Nepomuceno IB,Messner AH et al. A phase II doubleblind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Therapy 2002; 13:1349-59.
91. Alton EWFW, Middleton PG, Caplen NJ et al. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genet 1993; 5:135-42.
92. Bragonzi A, Conese M. Non-viral approach toward gene therapy of cystic fibrosis lung disease. Curr Gene Therapy 2002; 2:295-305.
93. Muszynshi-Kwan AT, Perlman R, Rivington-Law BA. Compliance with and effectiveness of chest physiotherapy in cystic fibrosis: a review. Physiother Can 1988; 40:28-30.
94. Passero M, Remor B, Solomon J. Patient reported compliance with cystic fibrosis therapy. Clin Pediatr 1981; 20:264-6.
95. Van der Schans C, Prasad A, Maine E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford, Update Software, 2003.
96. Hess DR. The evidence for secretions clearance techniques. Respir Care 2001; 46:1276-93.
97. Connors AF Jr,Hammon WE,Martin RJ,Rogers RM. Chest physical therapy: the immediate effect on oxygenation in acutely ill patients. Chest 1980; 78:559-64.
98. Pryor J,Webber BA, Hodson ME. Effect of chest physiotherapy on oxygen saturation in patients with cystic fibrosis. Thorax 1990; 45:77.
99. Horiuchi K, Jordan D,Cohen D,Kemper MC,Weissman C. Insights into the increased oxygen demand during chest physiotherapy. Crit Care Med 1997; 25:1347-51.
100. Button BM, Heine RG, Catto-Smith AG, Phelan PD. Postural drainage in cystic fibrosis: is there a link with gastro-oesophageal reflux. J Paediatr Child Health 1998; 34:330-4.
101. Ersson V, Carlson H,Mellstrom A,Ponten U,Hedstrond U,Kobsson S. Observations on intra-cranial dynamics during respiratory physiotherapy in unconscious neurosurgical patients. Acta Anaesthesiol Scand 1990; 34:99-103.
102. Williams MT. Chest physiotherapy and cystic fibrosis. Why is the most effective form of treatment still unclear? Chest 1994; 106:1872-80.
103. Reisman JJ, Rivington-Law B, Corey ML et al. Role of conventional physiotherapy in cystic fibrosis. J Pediatr 1988; 113:632-6.
104. McIlwaine PM, Wong LT, Peacock D, Davidson AGF. Long term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr 1997; 131:570-4.
105. Girard JP, Terki N. The Flutter VRP1: a new personal pocket therapeutic device used as an adjunct to drug therapy in the management of bronchial asthma. J Invest Allergol Clin Immunol 1994: 4:23-7.
106. Konstan MW, Stern RC,Doershuk CF. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr 1994; 124:689-93.
107. McIlwaine PM,Wong LT,Peacock P,Davidson GA. Long term comparative trial of positive expiratory pressure versus oscillating positive expiratory pressure (flutter) physiotherapy with the treatment of cystic fibrosis. J Pediatr 2001; 138:845-50.
108. Nixon PA, Orsenstein DM,Kelsey SF,Doershuk CF. The prognostic value of exercise testing of patients with cystic fibrosis. N Engl J Med 1992; 327:1785-8.
109. Hebestreit A,Kersting U, Basler B, Jeschke R,Hebestreit H. Exercise inhibits epithelial sodium channels in patients with cystic fibrosis. AmJ Respir Crit Care Med 2001; 164:443-6.
110. Bradley J, Moran F. Physical training for cystic fibrosis (Cochrane Review). In:The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
111. Selvadurai HC, Blimkie CJ, Meyers N, Mellis CM, Cooper PJ, Van Asperen PP. Randomised controlled study of in-hospital exercise training programs in children with cystic fibrosis. Pediatr Pulmonol 2002; 33:194-200.
112. Schneiderman-Walker J, Pollock SL, Carey M et al. A randomisedcontrolled trial of a 3 year home exercise program in cystic fibrosis. J Pediatr 2000; 136:304-10.
113. Baldwin DR, Hill AL, Peckham DG, Knox AJ. Effect of addition of exercise to chest physiotherapy on sputum expectoration and lung function in adults with cystic fibrosis. Respir Med 1994; 88:49-53.
114. Shah S, Capon DJ,Hellmiss R,Marsters SA,Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87:9188-92.
115. Robinson M,Hemming AL,Moriaty C, Ebert S, Bye PTP. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatr Pulmonol 2000; 30:16-24.
116. Laube BL,Auci RM, Shields DE et al. Effects of rhDN'ase on airflow obstruction and mucociliary clearance in cystic fibrosis. AmJ Respir Crit Care Med 1996; 153:752-60.
117. Kearney CE, Wallis CE. Deoxyribobonuclease for cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
118. Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolised recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331:637-41.
119. McCoy K,Hamilton S, Johnson C for the Pulmozyme Study Group. Effects of 12-week administration of dornase a in patients with advanced cystic fibrosis lung disease. Chest 1996; 110:889-95.
120. Ledson M J, Wahbi Z, Convery RP, Cowperthwaite C, Heaf DP, Walshaw MJ. Targeting of dornase a therapy in adult cystic fibrosis. J R Soc Med 1998; 91:360-4.
121. Bollert FGE,Paton JY,Marshall TG,Calvert J,Greening AP, Innes JA on behalf of the Scottish Cystic Fibrosis Group. Recombinant DN'ase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Eur Respir J 1999; 13:107-13.
122. Davies J,Trindale M-T,Wallis C,Rosenthal M,Crawford O,Bush A. Retrospective review of the effect ofDNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23:243-8.
123. Wilmott RW, Amin RS, Colin AA et al. Aerosolised recombinant human DNase in hospitalised cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996; 153:1914-17.
124. Konstan MW, Butler SM, Schidlaw DV et al. Patterns of medical practice in cystic fibrosis. Part II. Use of therapies. Pediatr Pulmonol 1999; 28:248-51.
125. Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995; 89:499-502.
126. Ranasinha C,AssoufiB, Shah S et al. Efficacy and safety of short term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993; 342:199-302.
127. Suri R,Metcalf C, Lees B et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001; 358:1316-21.
128. Zahm, J-M, Debordeaux C,Maurer C et al. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions. AmJ Respir Crit Care Med 2001; 163:1153-7.
129. Duijvestijn YCM,Brand PLP. Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatr 1999; 88:38-41.
130. Wills P,Hall R, Chan W-M, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997; 99:9-13.
131. Robinson M,Hemming A,Reqnis J et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52:900-3.
132. Shiburya Y,Wills PJ, Cole PJ. Effect of osmolality on muco-ciliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Respirology 2003; 8:121-5.
133. Winters SL, Yeates DB. Roles of hydration, sodium and chloride in regulation of canine mucociliary transport system. J Appl Physiol 1997; 83:1360-9.
134. Price AM,Webber SE,Widdicombe JG. Osmolality affects ion and water fluxes and secretion in the ferret trachea. J Appl Physiol 1993; 74:2788-94.
135. Peatfield AC, Richardson PS, Wells UM. The effect of airflow on mucus secretion into the trachea of the cat. J Physiol 1986; 380:429-39.
136. Eggleston P, Rosenstein BJ, Stackhouse CM, Alexander MF. Airway hyper-reactivity in cystic fibrosis. Clinical correlates and possible effects on the course of the disease. Chest 1988; 94:360-5.
137. Wark PAB, McDonald V. Nebulised hypertonic saline for cystic fibrosis (Cochrane Review). In:The Cochrane Library, Issue 1. Oxford, Update Software, 2003.
138. Robinson M,Regnis J,Bailey DL,King M,Bautovich G,Bye PTP. The effects of hypertonic saline, amiloride and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996; 153:1503-9.
139. Eng PA,Morton J, Douglass JA, Riedler J,Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulised hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996; 21:77-83.
140. Wills PJ,Chan WM,Hall RL,Cole PJ. Ciliary transportability of sputum is governed by its osmolality. In:Baum GL,Priel Z,Roth Y, Liron N, Ortfield EJ, eds. Cilia,Mucus and Microciliary Interactions. New York,Marcel Dekker, 1998:281-4.
141. Robinson M,Daviskas E,Ebert S et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14:678-85.
142. Ryan G,Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
143. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Oliver RE. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996; 51:364-8.
144. Ramsey BW,Pepe MS,Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30.
145. Quittner AL, Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002; 33:269-76.
146. Moss RB. Administration of aerosolised antibiotics in cystic fibrosis patients. Chest 2001; 120:1075-85.
147. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987; 19:831-8.
148. Hodson ME,Penketh ARL,Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas infections in patients with cystic fibrosis. Lancet 1981; ii:1137-9.
149. Stead RJ, Hodson ME, Button JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987; 81:272-9.
150. Hodson ME, Gallagher CG,Goven JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20:658-64.
151. Pedersen SS, Jensen T, Hoiby N, Koch N. Management of Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand 1987; 76:955-61.
152. Friederiksen B, Lanng S,Koch C,Hoiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21:153-8.
153. Breen L,Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
154. Brett MM, Simmonds EJ, Ghoneim ATM,Littlewood JM. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Arch Dis Child 1992; 67:1086-8.
155. Elborn JS,Prescott RJ, Stack BHR et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000; 55:355-8.
156. Sheldon CD, Assoufi BK, Hodson ME. Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respir Med 1993; 87:587-93.
157. Keagan MT, Johansen HK. Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis (Cochrane Review). In:The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
158. McCaffery K, Oliver RE,Franklin M,Mukhopadhpyay S. Systematic review of anti-staphylococcal antibiotic therapy in cystic fibrosis. Thorax 1999; 54:380-3.
159. Weaver LT,Green MR,Nicholson K et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994; 70:84-9.
160. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
161. Ratjen F, Gomes G,Paul K,Posselt HG,Wagner TO,Harms K. Effect of continuous anti-staphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001; 31:13-16.
162. Wheeler WB,Williams RN,Matthews WJ, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5 year longitudinal study. J Pediatr 1984; 104:695-9.
163. Burdon JG, Cade JF, Sutherland PW, Pain MC. Cystic fibrosis and bronchial hyperactivity: concomitant defects or cause and effect? Med J Aust 1980; 2:77-8.
164. Tobin MJ,Maguire D,Keen D,Tempony E,Fitzgerald MX. Atopy and bronchial reactivity in older patients with cystic fibrosis. Thorax 1980; 35:807-13.
165. Mareno RH,Hogg JC,Pare PD. Mechanics of airway narrowing. Am Rev Respir Dis 1986; 133:1171-80.
166. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
167. Auerbach HS,Williams M,Kilpatrick JA,Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2:686-8.
168. Greally P, Hussain PJ, Vergani D, Price JF. Interleukin-1a, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child 1994; 71:35-9.
169. Eigen H,Rosenstein BJ, Fitzsimmons S, Schidlow DV and the Cystic Fibrosis Foundation Prednisone Trial Group.A multicentre study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995; 126:515-23.
170. Lai HC, Fitzsimmons SC, Allen DB et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000; 342:851-9.
171. Dezateux C,Walters S, Balfour-Lynn I. Inhaled corticosteroids for cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
172. Balfour-Lynn I,Klein NJ,Denwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997; 77:124-30.
173. Bisgaard H,Pedersen SS,Nielsen KG et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. AmRev Respir Crit Care Med 1997; 156:1190-6.
174. Konstan MW,Vargo KM,Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. AmRev Respir Dis 1990; 141:186-92.
175. Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis (Cochrane Review). In:The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
176. Konstan MW,Hoppel CL, Choi B, Davis PB. Ibuprofen in children with cystic fibrosis (CF): pharmacokinetics and adverse effects: a randomised, double-blind, placebo-controlled, 3 month doseescalation study in children with cystic fibrosis. J Pediatr 1991; 118:956-64.
177. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-54.
178. Sordelli DD, Macri CN, Mailkie AJ, Cerquetti MC. A preliminary study of the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. Int J Immunopathol Pharmacol 1994; 7:109-17.
179. Vilbragrasa V, Besto L, Cortijo J et al. Effects of erythromycin on chemo-attractant-activated human polymorphonuclear leukocytes. Gen Pharmac 1997; 29:605-9.
180. Takizawa H, Desaki M, Ohtashi T et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. AmJ Respir Crit Care Med 1997; 156:266-71.
181. Khan AA, Slifer TR, Araujo FG et al. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999; 11:121-32.
182. Morikawa K,Watabe H,Aroahe M et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. J Antimicrob Agents Chemother 1996; 40:1366-70.
183. Black PN. Anti-inflammatory effects of macrolide antibiotics. Eur Respir J 1959; 10:971-2.
184. Jaffe A,Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001; 31:464-73.
185. Molinari G, Guzman CA, Pesce A et al. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31:681-8.
186. Fisher JJ, Bauman U, Gudowius P et al. Azithromycin reduces epithelial adherence of P. aeruginosa in patients with cystic fibrosis (abstract). Pediatr Pulmonol 1999; Suppl 19:265.
187. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax 1997; 52:915-18.
188. Hoiby H. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994; 49:531-2.
189. Peckham DG. Macrolide antibiotics and cystic fibrosis: do the macrolides have a role in the treatment of cystic fibrosis? Thorax 2002; 57:189-90.
190. Ichimaya T, Takeoka K,Hiramatsu K,Hirai K,Yamasaki T,Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996; 42:186-91.
191. Jaffe A,Francis J,Rosenthal M et al. Long term azithromycin may improve lung function with cystic fibrosis. Lancet 1998; 351:420.
192. Wolter J, Seeney S, Bell S, Bowler S,Mosel P,McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212-16.
193. Equi A, Balfour-Lynn IM, Bush A, Rosethal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled, crossover trial. Lancet 2002; 360:978-84.
194. De Sant'Agnese PA. Pulmonary manifestations of fibrocystic disease of pancreas. Dis Chest 1955; 27:654-67.
195. Hordvik NL,Konig P,Morris D,Kreutz C,Barbero GJ. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis 1985; 131:889-93.
196. Wolter JM, Bowler SD,McCormack JG. Are anti-pseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis? Aust NZ J Med 1999; 29:15-21.
197. Lang BJ,Aaron SD, Ferris W,Herbert PC,Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multi-resistant strains of Pseudomonas aeruginosa. AmJ Respir Crit Care Med 2000; 162:2241-5.
198. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
199. Smith AL, Doershuk C, Goldmann D et al. Comparison of a blactam alone versus b-lactam and an amino-glycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134:413-21.
200. Spivey JM. The post antibiotic effect. Clin Pharm1992; 11:865-75.
201. De Groot R, Smith AL. Antibiotic pharmacokineics in cystic fibrosis. Differences and clinical significance. Clin Pharm1987; 13:228-53.
202. Tan K, Bunn H. Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
203. Merco T, Asencio O, Bosque M, de Gracia J, Serra C. Home intravenous antibiotics for cystic fibrosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
204. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomised trial examining clinical quality of life and cost aspects. Eur Respir J 1997; 10:896-900.
205. Homnick DN, Anderson K, Marks JH. Comparison of the Flutter device to standard chest physiotherapy in hospitalised patients with cystic fibrosis: a pilot study. Chest 1998; 114:993-7.
206. Gondor M,Nixon PA,Mutich R,Rebovich PL,Qrenstein DM. Comparison of Flutter device and chest physical therapy in the treatment of cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol 1999; 28:255-60.
207. Hordvik NL, Sammut PH, Judy CG, Strizek SJ, Colombo JL. The effects of albuterol on the lung function of hospitalised patients with cystic fibrosis. AmJ Respir Crit Care Med 1996; 154:156-60.
208. Hordvik NL,Sammut PH,Judy CG,Colombo JL. Effects of standard and high doses of salmeterol on lung function of hospitalised patients with cystic fibrosis. Pediatr Pulmonol 1999; 27:43-53.
209. Bowler IM,Kelman B,Worthington D et al. Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch Dis Child 1995; 73:427-30.
210. Madden BP, Kariyawasam H, Siddiqi AJ, Machin A, Pryor JA, Hodson ME. Noninvasive ventilation in cystic fibrosis patients with acute on chronic respiratory failure. Eur Respir J 2002; 19:310-13.
211. Sod N, Paradowski LJ, Yankaskas JR. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001; 163:335-8.